Copper histidinate is a medicine for children with Menkes disease, a rare genetic condition where the body can't absorb copper from food. It is given as a shot under the skin. It works by delivering copper straight into the body so it doesn't have to pass through the gut.
Every report comes from a Lived member, sent anonymously.
Have you tried Zycubo (Copper Histidinate) for Menkes Disease?
Zycubo (copper histidinate) is a prescription copper injection for children with Menkes disease. It was approved by the FDA in 2026 as the first treatment made specifically for this condition. Menkes disease is a rare inherited disorder in which the body cannot absorb copper properly from food or move it to where it is needed. Many enzymes need copper to work, so the shortage causes seizures, weak muscle tone, developmental problems and fragile connective tissue, usually starting in the first months of life. Without treatment, most affected children die before age 3. Zycubo is not approved for occipital horn syndrome, a milder disorder caused by changes in the same gene that mainly affects bones and connective tissue.
Menkes disease is caused by changes in the ATP7A gene, which makes a protein that carries copper across cell membranes. Because the gene is on the X chromosome, the disease mainly affects boys. When the protein does not work, copper from food is poorly absorbed, blood levels fall, copper does not pass normally into the brain, and copper-dependent enzymes cannot do their jobs. Zycubo delivers copper bound to histidine, an amino acid, as an injection under the skin. This bypasses the gut entirely, so copper reaches the bloodstream and blood copper levels rise. It replaces the missing copper but does not repair the faulty transport protein, and how fully the extra copper reaches the brain and other tissues has not been worked out.
Zycubo is given as an injection just under the skin (subcutaneous). Children younger than 1 year usually receive it twice a day, 8 to 12 hours apart, and children 1 year and older once a day. Each dose comes from a single-use vial of powder that is mixed with salt water before injecting. After training, a parent or other caregiver can give the injections at home if the care team agrees. Injections go into the belly (about 2 inches from the navel), buttocks, outer upper arm or outer thigh. Rotating to a different site each time lowers the chance of lipodystrophy, a lumpy or dented change in the fat under the skin, and the injections should not go into skin that is bruised, scarred, red, hard or tender. If a dose is missed, give it as soon as possible and wait at least 6 hours before the next scheduled dose.
Redness, swelling or other reactions at the injection site occurred in about 7% of children in the studies. The studies involved very ill children and had no comparison group receiving a placebo, so it is hard to tell which problems came from the medicine and which from Menkes disease itself. The problems reported most often during treatment were infections (especially pneumonia), breathing difficulties, seizures, bleeding, low blood pressure, vomiting, diarrhea, fever, dehydration, fast heart rate and broken bones. Anemia (a low red blood cell count) and raised liver enzymes were also reported, and these are among the effects that copper buildup can cause.
The main risk of Zycubo is too much copper. Menkes disease already causes copper to build up in some organs, and adding copper can push levels high enough to injure the kidneys, harm the liver, and disturb the bone marrow, spleen and iron handling, which can lead to anemia. The risk is highest in the first two years of life, when the kidneys and liver are still immature. This damage usually shows up on blood and urine tests before it causes obvious symptoms, which is why testing is built into treatment. Copper levels, kidney and liver function, salts in the blood such as sodium, potassium and phosphate, and a complete blood count are checked before starting, then every 6 weeks for the first 6 months, every 3 months for the next 18 months, and every 6 months after that. If results become abnormal, the care team may give doses less often, pause treatment or stop it, and may add electrolyte supplements. The label lists no known drug interactions and no situations in which Zycubo must never be used. Zycubo should not be mixed in the same syringe with other medicines.
Timing matters more with Zycubo than with most medicines. In the studies, children with severe forms of Menkes disease who started treatment within 4 weeks of birth (adjusted for prematurity) lived much longer than similar untreated children: about half were still alive at the end of follow-up, compared with about 1 in 8 untreated children, and their median survival was roughly 15 years rather than about a year and a half. Children who started later also lived longer than untreated children, but the gain was smaller. These results come from comparing treated children with a separate untreated group rather than a randomized trial. Treatment does not cure Menkes disease. Better development has been reported in some children treated early, not all, and responses vary widely. Daily life involves one or two injections a day, regular blood and urine tests, and ongoing follow-up with the care team, who use those results to keep copper replacement high enough to help without building up to harmful levels.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Zycubo (Copper Histidinate), what you've noticed, or ask the community a question.